GenZum Life Sciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Genzum Life Sciences is a private, US-based pharmaceutical development company specializing in complex generics and 505(b)(2) products, with a core focus on topical and sterile formulations. Founded in 2018, it operates as a product development and out-licensing partner, co-investing with commercial partners to bring difficult-to-develop products to market. The company leverages a team of industry veterans to manage development from formulation through Phase III studies, aiming to reduce drug costs and create market value through strategic global partnerships.

OncologyImmunology

Technology Platform

Specialized expertise in formulation science and clinical trial design for complex generic and 505(b)(2) pharmaceutical products, with a core focus on topical and sterile dosage forms.

Pipeline

2

2 drugs in pipeline2 in Phase 3

Drug	Indication	Stage	Watch
Naftifine hydrochloride 2% + Placebo + Naftin® 2% (Naftifine...	Tinea Pedis	Phase 3
cataract surgery	Bilateral Cataract	Phase 3

Opportunities

The large and growing market for complex generics, particularly in topical and sterile injectable forms, presents a significant opportunity.

Genzum's partnership model allows it to access this market with reduced commercial risk, focusing on high-value products with limited competition.

The global push for lower drug costs further strengthens the demand for its services.

Risk Factors

Key risks include the high technical failure rate of complex generic development, potential patent litigation from originator companies, intense competition for lucrative targets, and dependence on securing and maintaining partnerships with larger pharmaceutical firms for funding and commercialization.

Competitive Landscape

Genzum competes with other specialized generic development companies, the in-house R&D divisions of large generic pharmaceutical firms (e.g., Teva, Mylan, Hikma), and contract development organizations. Its competitive edge is its focused expertise on high-barrier topical and sterile products and its asset-light, partnership-centric business model.

More companies in Biologics / Biosimilars →More companies in United States →